Quality of life in patients receiving medicines for prostate cancer : What do clinicians think is important?

Dunlop, Emma and Karlsson-Brown, Steven and Laskey, Jennifer and Bennie, Marion and Baillie, Kelly and Clarke, Julie (2018) Quality of life in patients receiving medicines for prostate cancer : What do clinicians think is important? Journal of Oncology Pharmacy Practice, 24 (8). pp. 54-55. ISSN 1477-092X

[img]
Preview
Text (Dunlop-etal-BOPA-2018-Quality-of-life-in-patients-receiving-medicines)
Dunlop_etal_BOPA_2018_Quality_of_life_in_patients_receiving_medicines.pdf
Accepted Author Manuscript

Download (945kB)| Preview
    [img]
    Preview
    Text (Dunlop-etal-BOPA-2018-Quality-of-life-in-patients-receiving-medicines-for-prostate-cancer)
    Dunlop_etal_BOPA_2018_Quality_of_life_in_patients_receiving_medicines_for_prostate_cancer.pdf
    Accepted Author Manuscript

    Download (282kB)| Preview

      Abstract

      Objectives: In addition to clinical outcomes it is increasingly recognised that Patient Reported Outcomes (PROMs) are a useful measure of benefit of cancer medicines. Although verbally discussed in clinic appointments, the impact cancer medicines have on quality of life (QoL) is not consistently documented in routine clinical practice. Recent studies have shown that utilising QoL tools can have a positive impact on clinician decision-making and improve patient outcomes.1,2 Many PROMs tools exist, but there is limited evidence on which may best support assessing the impact cancer medicines have on QoL as part of routine clinical care.